A Study of Ibrutinib in Combination With Rituximab, in Japanese

See also
Status	Clinical Trial	Phase
Enrolling by invitation	`NCT01804686` - A Long-term Extension Study of PCI-32765 (Ibrutinib)	Phase 3
Completed	`NCT03630042` - Investigating the Safety and Efficacy of Rituximab and Pembrolizumab in Relapsed/Refractory Waldenström's Macroglobulinaemia	Phase 2
Completed	`NCT02916979` - Myeloid-Derived Suppressor Cells and Checkpoint Immune Regulators' Expression in Allogeneic SCT Using FluBuATG	Phase 1
Active, not recruiting	`NCT05024045` - Study of Oral LOXO-338 in Patients With Advanced Blood Cancers	Phase 1
Recruiting	`NCT05952037` - Study to Evaluate the Efficacy and Safety of BGB-11417 in Participants With Waldenström's Macroglobulinemia	Phase 2
Completed	`NCT01527045` - Donor Atorvastatin Treatment in Preventing Severe Acute GVHD After Nonmyeloablative Peripheral Blood Stem Cell Transplant in Patients With Hematological Malignancies	Phase 2
Recruiting	`NCT03679455` - A Study of Obinutuzumab (RO5072759) Induction in Patients With Relapsed/ Refractory Waldenström Macroglobulinemia, OBI-1	Phase 2
Not yet recruiting	`NCT05099471` - Efficacy of Venetoclax in Combination With Rituximab in Waldenström's Macroglobulinemia	Phase 2
Not yet recruiting	`NCT04830046` - Covid-19 Vaccine Responsiveness in MM and Waldenstrom
Terminated	`NCT02109224` - Ibrutinib in Treating Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma in Patients With HIV Infection	Phase 1
Completed	`NCT01093586` - Donor Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Malignancies	Phase 2
Active, not recruiting	`NCT03620903` - Efficacy of First Line B-RI for Treatment Naive Waldenström's Macroglobulinemia	Phase 2
Not yet recruiting	`NCT04702932` - Establishment of Genomic, Transcriptomic and Functional Characteristics of Tumor Cells in Hyperinflammatory Hemopathies
Active, not recruiting	`NCT03133221` - 1630GCC: Zydelig Maintenance in B-Cell Non-Hodgkin's Lymphoma After Autologous Stem Cell Transplantation	Phase 2
Completed	`NCT00608361` - Dasatinib in Treating Patients With Solid Tumors or Lymphomas That Are Metastatic or Cannot Be Removed By Surgery	Phase 1
Completed	`NCT00777738` - Efficacy of Bortezomib (Velcade(R)) in Patients With Advanced Waldenström Macroglobulinemia	Phase 2
Completed	`NCT00438880` - Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma	Phase 1/Phase 2
Active, not recruiting	`NCT00075478` - Total-Body Irradiation With or Without Fludarabine Phosphate Followed By Donor Stem Cell Transplant in Treating Patients With Hematologic Cancer	Phase 3
Completed	`NCT01272817` - Nonmyeloablative Allogeneic Transplant	N/A
Recruiting	`NCT04116437` - Zanubrutinib (BGB-3111) in Participants With Previously Treated B-Cell Lymphoma Intolerant of Prior Bruton Tyrosine Kinase Inhibitor (BTKi) Treatment	Phase 2

NCT number	NCT04062448
Study type	Interventional
Source	Janssen Pharmaceutical K.K.
Contact
Status	Completed
Phase	Phase 2
Start date	September 25, 2019
Completion date	March 2, 2023

A Study of Ibrutinib in Combination With Rituximab, in Japanese Participants With Waldenstrom's Macroglobulinemia (WM)

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms